AccScience Publishing / GTM / Volume 1 / Issue 2 / DOI: 10.36922/gtm.v1i2.94
Cite this article
10
Download
10
Citations
55
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

The status of compensated cirrhosis might be negatively associated with the tumor size in patients with hepatitis B virus-related hepatocellular carcinoma

Yanna Liu1† Xiangjun Qian2† Congying Wu3 Weidong Pan2 Jingmin Zhao4 Xiangmei Chen1* Fengmin Lu1,5*
Show Less
1 Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing 100191, China
2 Department of Pancreatic-Hepatobiliary Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China
3 Institute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing 100191, China
4 Department of Pathology and Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
5 Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
Global Translational Medicine 2022 , 1(2), 94; https://doi.org/10.36922/gtm.v1i2.94
Submitted: 12 May 2022 | Accepted: 22 July 2022 | Published: 12 August 2022
© 2022 by the Authors. Licensee AccScience Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Liver cirrhosis has been a well-known risk factor for the development of hepatocellular carcinoma (HCC). However, this view has recently been challenged. This study aimed to investigate the potential association of cirrhosis with hepatitis B virus (HBV)-related HCC. In this study, two independent multicenter clinical cohorts that included 1,431 HCC patients with chronic HBV infection were retrospectively studied. The first cohort consisted of 334 HCC patients undergoing curative resection and cirrhosis, who have been pathologically diagnosed. The second cohort consisted of 1,087 HCC patients, who have been diagnosed for the presence of cirrhosis based on clinical evidence. Patients of each cohort were further divided into different subgroups according to the presence of cirrhosis and the severity of the cirrhosis. In both cohorts, patients with cirrhosis had smaller tumor size compared to those without cirrhosis (P < 0.05) and a relatively lower proportion of large tumor, defined as tumor size > 5 cm in diameter (P < 0.05). Patients with decompensated cirrhosis had the highest rate of vascular invasion and/or extrahepatic metastases compared with compensated cirrhosis and non-cirrhosis (53.0% vs. 24.8% vs. 26.9%, P < 0.001). In the first cohort, globulin (odds ratio [OR] = 1.096, P = 0.001) and vascular invasion (OR = 4.013, P = 0.013) were independent risk predictors of HCC tumor size >5 cm, while cirrhosis stage Laennec 4B/C was a protective factor (OR = 0.372, P = 0.002). Similar results were observed in the second cohort. In conclusion, this study implied that HCC patients with compensated cirrhosis tend to harbor smaller tumor, but severe cirrhosis favors tumor vascular invasion and metastasis.

Keywords
Liver cirrhosis
Hepatocellular carcinoma
Hepatitis B virus
Neoplasm metastasis
Vascular invasion
Funding
National S and T Major Project for Infectious Diseases
National Natural Science Foundation of China
References
[1]

Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71: 209–249. https://doi.org/10.3322/caac.21660 

[2]

Seitz HK, Stickel F, 2006, Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem, 387: 349–360. https://doi.org/10.1515/BC.2006.047

[3]

Yuen MF, Tanaka Y, Fong DY, et al., 2009, Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol, 50: 80–88. https://doi.org/10.1016/j.jhep.2008.07.023

[4]

Lok AS, Seeff LB, Morgan TR, et al., 2009, Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology, 136: 138–148. https://doi.org/10.1053/j.gastro.2008.09.014

[5]

Zhang DY, Friedman SL, 2012, Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology, 56: 769–775. https://doi.org/10.1002/hep.25670

[6]

Massarweh NN, El-Serag HB, 2017, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control, 24: 1073274817729245. https://doi.org/10.1177/1073274817729245

[7]

Idilman R, De Maria N, Colantoni A, et al., 1998, Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepatitis, 5: 285–299. https://doi.org/10.1046/j.1365-2893.1998.00116.x

[8]

Chayanupatkul M, Omino R, Mittal S, et al., 2017, Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol, 66: 355–362. https://doi.org/10.1016/j.jhep.2016.09.013

[9]

Garrido A, Djouder N, 2021, Cirrhosis: A questioned risk factor for hepatocellular carcinoma. Trends Cancer, 7: 29–36. https://doi.org/10.1016/j.trecan.2020.08.005

[10]

Zhu M, Lu T, Jia Y, et al., 2019, Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease. Cell, 177: 608–621.e612. https://doi.org/10.1016/j.cell.2019.03.026

[11]

Chen YL, Ko CJ, Chien SY, et al., 2011, Tumor size as a prognostic factor in resected small hepatocellular carcinoma: A controversy revisited. J Gastroenterol Hepatol, 26: 851–857. https://doi.org/10.1111/j.1440-1746.2010.06595.x

[12]

Zhang W, Wang X, Jiang R, et al., 2015, Effect of tumor size on cancer-specific survival in small hepatocellular carcinoma. Mayo Clin Proc, 90: 1187–1195. https://doi.org/10.1016/j.mayocp.2015.06.018

[13]

Albillos A, Lario M, Álvarez-Mon M, 2014, Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. J Hepatol, 61: 1385–1396. https://doi.org/10.1016/j.jhep.2014.08.010

[14]

Mehendale HM, 2005, Tissue repair: An important determinant of final outcome of toxicant-induced injury. Toxicol Pathol, 33: 41–51. https://doi.org/10.1080/01926230590881808

[15]

Bourbonnais E, Raymond VA, Ethier C, et al., 2012, Liver fibrosis protects mice from acute hepatocellular injury. Gastroenterology, 142: 130–139.e4. https://doi.org/10.1053/j.gastro.2011.09.033

[16]

Nishio T, Iimuro Y, Nitta T, et al., 2003, Increased expression of collagenase in the liver induces hepatocyte proliferation with cytoplasmic accumulation of beta-catenin in the rat. J Hepatol, 38: 468–475. https://doi.org/10.1016/s0168-8278(03)00013-8

[17]

Zhou XY, Jamil A, Nash A, et al., 2006, Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells implications for regulation of liver fibrosis. J Biol Chem, 281: 39757–39765. https://doi.org/10.1074/jbc.M605621200

[18]

Lashen SA, Elshafei MM, Hablass FH, et al., 2020, Liver stiffness as a predictor of hepatocellular carcinoma behavior in patients with hepatitis C related liver cirrhosis. Hepatobiliary Pancreat Dis Int, 19: 22–28. https://doi.org/10.1016/j.hbpd.2019.11.004

[19]

Giannini EG, Sammito G, Farinati F, et al., 2014, Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. Cancer, 120: 2150–2157. https://doi.org/10.1002/cncr.28706

[20]

Rhim AD, Oberstein PE, Thomas DH, et al., 2014, Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell, 25: 735–747. https://doi.org/10.1016/j.ccr.2014.04.021 

[21]

Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al., 2014, Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell, 25: 719–734. https://doi.org/10.1016/j.ccr.2014.04.005

[22]

DuChez BJ, Doyle AD, Dimitriadis EK, et al., 2019, Durotaxis by human cancer cells. Biophys J, 116: 670–683. https://doi.org/10.1016/j.bpj.2019.01.009

[23]

Plotnikov SV, Pasapera AM, Sabass B, et al., 2012, Force fluctuations within focal adhesions mediate ECM-rigidity sensing to guide directed cell migration. Cell, 151: 1513–1527. https://doi.org/10.1016/j.cell.2012.11.034

[24]

Gao J, Rong Y, Huang Y, et al., 2019, Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP. J Cell Physiol, 234: 2639–2648. https://doi.org/10.1002/jcp.27078

[25]

Prager-Khoutorsky M, Lichtenstein A, Krishnan R, et al., 2011, Fibroblast polarization is a matrix-rigidity-dependent process controlled by focal adhesion mechanosensing. Nat Cell Biol, 13: 1457–1465. https://doi.org/10.1038/ncb2370

[26]

Deng Y, Pang Q, Miao RC, et al., 2016, Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. Onco Targets Ther, 9: 5317–5328. https://doi.org/10.2147/OTT.S109736

[27]

Vawda S, Mansour R, Takeda A, et al., 2014, Associations between inflammatory and immune response genes and adverse respiratory outcomes following exposure to outdoor air pollution: A HuGE systematic review. Am J Epidemiol, 179: 432–442. https://doi.org/10.1093/aje/kwt269

[28]

Du XJ, Tang LL, Mao YP, et al., 2014, The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PLoS One, 9(4): e94473. https://doi.org/10.1371/journal.pone.0094473

Conflict of interest
The authors declared no conflict of interest related to this article.
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021, Print ISSN: TBA, Published by AccScience Publishing